Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD99 reactivity in mesenchymal chondrosarcoma

S R Granter1, A A Renshaw, C D Fletcher

  • 1Departments of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Human Pathology
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current status of immunotherapy for gastrointestinal stromal tumor.

Cancer gene therapy·2017
Same author

2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase.

Diabetes, obesity & metabolism·2016
Same author

Omega-3 fatty acids prevent early-life antibiotic exposure-induced gut microbiota dysbiosis and later-life obesity.

International journal of obesity (2005)·2016
Same author

Induction with Rabbit Antithymocyte Globulin following Orthotopic Liver Transplantation for Hepatitis C.

International journal of organ transplantation medicine·2014
Same author

Studies on some genetic parameters of rice (Oryza sativa L.).

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2014

CD99 reactivity is a sensitive marker for Ewing's sarcoma (ES) and primitive neuroectodermal tumors (PNET). However, mesenchymal chondrosarcoma also shows strong CD99 reactivity, making it indistinguishable from ES/PNET based on this marker alone.

Area of Science:

  • Oncology
  • Pathology
  • Immunohistochemistry

Background:

  • CD99 is a known sensitive and specific marker for Ewing's sarcoma (ES) and primitive neuroectodermal tumors (PNET).
  • The specificity of CD99 in differentiating various small round blue cell tumors requires further investigation.

Purpose of the Study:

  • To evaluate the CD99 immunoreactivity in mesenchymal chondrosarcoma.
  • To determine if CD99 can differentiate mesenchymal chondrosarcoma from ES/PNET.

Main Methods:

  • Immunohistochemical analysis of CD99 expression using the O13 antibody.
  • Evaluation of 11 cases of mesenchymal chondrosarcoma.

Main Results:

  • All 11 mesenchymal chondrosarcoma cases (100%) exhibited strong CD99 reactivity in the small round blue cell component.

Related Experiment Videos

  • Staining was consistently membranous, involving over 50% of cells.
  • Cartilaginous areas showed absent or weak focal staining.

    • Conclusions:

    • Mesenchymal chondrosarcoma demonstrates significant CD99 immunoreactivity.
    • CD99 expression alone is insufficient to distinguish mesenchymal chondrosarcoma from ES/PNET.